ArcticZymes Technologies (AZT)

TekBot · juni 17, 2024, 1:00pm

ArcticZymes Technologies executes contract with consortium for Advanced therapies enzyme project funded by The Research Council of Norway

Tromsø, Norway, June 17, 2024 - ArcticZymes Technologies ASA (OSE: AZT) has
today executed a contract with The Research Council of Norway, securing up to
11.8 MNOK for a collaborative project aimed at supporting the advanced therapy
…

Vis børsmeldingen

biomanufacturing sector.

This follows a previously announced research grant awarded by the Norwegian
Research Council. The agreements with the Norwegian Research Council and the
project partners, the University of Tromsø - The Arctic University of Norway,
and SINTEF Industri have now been finalized, marking the project’s commencement.
The project has been named AdEPT - Advancing Enzymes for Precision Therapeutics
and will run from 2024 through 2027.

In recent years, ArcticZymes Technologies has successfully provided enzymes for
manufacturing viral vectors used in cell and gene therapy, as well as vaccines.
Viral vectors and nucleic acids like RNA and DNA are increasingly utilized in
advanced therapy medicinal products. Enzymes play a crucial role in the
manufacturing, analytics, and quality control of these therapeutic RNAs and
DNAs. However, significant technical challenges remain, including development
costs, commercial scale manufacturing, and sufficient quality for therapeutic
use. The project, AdEPT, aims to address these challenges by developing novel
enzyme solutions for the manufacturing and analysis of therapeutic RNA.

CEO Michael B. Akoh stated: “I am pleased to see that we are executing on our
strategy to build a unique portfolio of enzymes within the advanced therapies
biomanufacturing segment. The collaboration with the University of Tromsø and
SINTEF Industri, and funding from The Research Council of Norway provides an
excellent foundation. I look forward to following the project’s progress over
the coming years and witnessing the emergence of new prototypes that can help
realize the potential of the many new therapeutic modalities currently in
development.”

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who develop therapeutics, in
vitro diagnostics, and molecular research kit products. Our mission is to make
our customers lives easier by unlocking new solutions to enhance quality of life
and create a more sustainable healthy world.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who develop therapeutics, in
vitro diagnostics, and molecular research kit products. Our mission is to make
our customers lives easier by unlocking new solutions to enhance quality of life
and create a more sustainable healthy world. For more information, please visit
the website: www.arcticzymes.com

Kilde

TekBot · juni 25, 2024, 6:27am

ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board

Tromsø, Norway - June 25, 2024 - ArcticZymes Technologies (OSE:AZT) is pleased
to announce the nomination of Dr. Frank Mathias as the new Chairman of the
Board.
…

Vis børsmeldingen

Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the
cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler
Biopharma SE, which he successfully developed into a leading global, full
-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a
publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias
has held senior roles at leading global pharmaceutical companies, including
Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he
was awarded the “EY Entrepreneur of the Year” title in Germany. Dr. Mathias is a
pharmacist by training and completed his Doctorate in Pharmacy at Paris VI
University.

“We are very pleased to nominate Frank Mathias as our new Chairman of the
Board,” said Jon R. Sandberg, Chairman of the Nomination Committee. “Frank
Mathias’ extensive experience and visionary leadership make him the ideal
candidate to guide our company into its next phase of development,
commercialization and growth.”

“I am honoured to join ArcticZymes at such a pivotal time,” said Dr. Frank
Mathias. “The innovative enzyme solutions developed by ArcticZymes have made
significant contributions to advancements in biomanufacturing, enhancing
efficiency and quality across the industry. I look forward to contributing to
the company’s continued success and collaborative growth.”

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

ir@arcticzymes.com

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who develop therapeutics, in
vitro diagnostics, and molecular research kit products. Our mission is to make
our customers lives easier by unlocking new solutions to enhance quality of life
and create a more sustainable healthy world.

Kilde

TekBot · juni 25, 2024, 8:05am

ArcticZymes Technologies ASA - flagging av fullmakter

TekBot · juni 26, 2024, 3:04pm

ArcticZymes Technologies ASA - Minutes form Annual General Meeting 2024

TekBot · juni 28, 2024, 8:40am

ArcticZymes Technologies ASA: Increase of share capital related to exercise of options

Tromsø, Norway, 28 June 2024 - ArcticZymes Technologies ASA (OSE: AZT) will
increase its share capital related to exercise of options by former board member
Marie Roskrow.
…

Vis børsmeldingen

The Board of Directors in ArcticZymes Technologies ASA) (OSE: AZT) have
to fulfil the Company’s obligations under the share option agreements and
in accordance with the authorization granted by the general meeting on 26 June
2024, resolved to increase the Company’s share capital by NOK 200,000 by
issuance of 200,000 new shares.

The capital increase is expected to be registered within 7 days, and
following the issuance of the new shares. The issued share capital of
ArcticZymes Technologies ASA will be NOK 51,071,390 consisting of 51,071,390
shares, each with a par value of NOK 1.00 after the capital increase is
registered.

The information included in this announcement is such that the Company
is required to disclose in accordance with the EU Market Abuse Regulation (MAR)
section and 19 and section 5-12 of the Norwegian Securities Trading Act.

The announcement is made by CFO Børge Sørvoll, 28 June 2024, at 10.40 CET.

For more information, please contact:
Børge Sørvoll
CFO
+47 95290187
ir@arcticzymes.com

Kilde

TekBot · juli 8, 2024, 8:23am

ArcticZymes Technologies ASA: Registration of share capital following exercise of options

ior · juli 31, 2024, 5:36pm

Repligen Corporation
Guidance: The company narrowed its revenue guidance within the previous range for fiscal year 2024, while adjusted EPS guidance remained unchanged

markets.businessinsider.com/news/stocks/repligen-reports-second-quarter-2024-financial-results-1033611256

Roche
Lifts 2024 profit guidance on strong drug sales

https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lifts-2024-profit-guidance-drug-sales-2024-07-25/

GSK
GSK’s momentum this year continues with excellent second quarter performance
Q2 sales grew in all areas

https://www.gsk.com/media/11412/q2-2024-results-announcement.pdf

Pfizer
Beats expectations in Q2 operating results, raising yearly guidance

‘A really nice print’: Healthcare analyst on Pfizer’s Q2 results – BNN Bloomberg

Sanofi
Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

Johnson & Johnson
Increases Full-Year 2024 operational sales

https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-reports-Q2-2024-results/default.aspx

Novartis
Novartis continues to deliver strong sales growth and core
margin expansion in Q2; raises FY 2024 bottom-line guidance

https://www.novartis.com/sites/novartis_com/files/q2-2024-media-release-en.pdf

Abbott
Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
Reports increase in Q2 2024 total worldwide sales

https://www.medicaldevice-network.com/news/abbott-q2-worldwide-sales/

Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth

Siemens Healthineers
Hit by China order delays in Q3, but sees 2025 turnaround

https://www.reuters.com/business/healthcare-pharmaceuticals/siemens-healthineers-misses-q3-expectations-due-slow-china-2024-07-31/

Surge in pharma & healthcare deals in Q2

http://timesofindia.indiatimes.com/articleshow/111789718.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

AstraZeneca, Roche, Sanofi Raise 2024 Outlooks on Strong Q2 Sales

AstraZeneca, Roche, Sanofi Raise 2024 Outlooks on Strong Q2 Sales - BioSpace

Staylong · juli 31, 2024, 7:40pm

Takk for oppsummeringen.

zap1994 · august 10, 2024, 11:49am

Ser ut til at d kanskje kan begynne å lysne. Har troa🙏

TekBot · august 15, 2024, 1:43pm

ArcticZymes Technologies ASA: Invitation to presentation of Q2 and 6M 2024 results

TekBot · august 22, 2024, 5:01am

ArcticZymes Technologies Q2 and 6M 2024 Results - progress in partnership discussions and portfolio development

Tromsø, Norway, August 22[nd], 2024 - ArcticZymes Technologies (OSE: AZT)
reported revenues of NOK 27.5 million and an EBITDA of NOK 2.6 million for the
second quarter of 2024.
…

Vis børsmeldingen

Highlights from Q2 and first 6M 2024

· ArcticZymes Technologies (AZT) had Q2 revenue of NOK 27.5 million (Q2 2023:
NOK 28.2 million) and NOK 57.6 for the first 6 months of 2024 (6M 2023: NOK 59.4
million)
· AZT had a positive EBITDA for Q2 of NOK 2.6 million (Q2 2023: NOK 6.8
million) and a net profit of NOK 2.7 million (Q2 2023: NOK 5.6 million). For the
first 6 months, EBITDA was NOK 4.9 million (6M 2023: NOK 13.0 million) and a net
profit of NOK 5.8 million (6M 2023: NOK 10.6 million)

· Operating expenses for Q2 were 25.0 million (Q2 2023: NOK 21.4 million)
where extraordinary items related implementation of a new ERP solution accounted
for NOK 1.4 million. For the first 6 months, operating expenses are at NOK 52.7
million (6M 2023: NOK 46.4 million). Expenses er are in line with expectations.

· Cash flow for Q2 was negative NOK -2.7 million (Q2 2023: NOK 6.9 million)
and NOK -10.6 million for the first 6 months explained by decrease in operating
cash flow of NOK -3.6 million, NOK -5.1 million in investing cash flow and NOK
-1.9 million in finance cash flow, giving a cash balance of NOK 170.3 million.
In addition, NOK 71 million is invested in low-risk interest rate funds
· Significant progress made in regard to distribution partnerships as well as
a CDMO agreement on SAN.
· Q2 was challenging in terms of lower average value per order but also an all
-time high number of orders indicating continued activity in both core segments
· Two patents filed during the summer. One for utilizing salt-active nucleases
in a new novel approach and one for new nuclease enzyme compositions and method
of use for processing and analysis of RNA.
· All development projects proceeded according to plan enabling the launch of
two new GMP grade nucleases and one ELISA kit within the next 12 months.

CEO Michael B. Akoh comments:

"In Q2, we made substantial progress in our partnership discussions,
particularly in regard to distribution and CDMO opportunities. We anticipate a
distribution agreement for SAN by Q4/Q1, which should be part of driving growth
in 2025.

Our internal development efforts remain strong, with plans to launch two new GMP
-grade nucleases and a new ELISA kit within the next 12 months. This will
position ArcticZymes with one of the most robust and advanced nuclease
portfolios in the industry.

We will continue to strengthen our portfolio and commercial position. We are
encouraged by the record number of orders in Q2, signalling continued activity
and demand for our products."

-Ends-

Presentation and Webcast
The Company will host a virtual Q2 and 6M 2024 presentation for investors,
analysts and media at 08:30 CET on Thursday, 22 August, 2024.

The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll.

The presentation can be followed as a live webcast from Hegnar TV on:
https://channel.royalcast.com/webcast/hegnarmedia/20240822_5 or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.

The report for Q2 and 6M 2024 will be available on www.newsweb.no and on the
company’s homepage www.arcticzymes.com from 07.00 CET on Thursday, 22 August
2024.

For more information, please contact:

CEO, Michael B. Akoh
Tel: +46 (0) 70
CFO, Børge
262 37 15
Sørvoll
Tel: +47 95 29 01

87

ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

Kilde

TekBot · august 22, 2024, 5:01am

ArcticZymes Technologies ASA Q2 and 6M Presentation

Kronn · september 3, 2024, 11:40am

Snakk om rykke tilbake til start, skjer her for tiden ?
Det ser ut som Azt trenger en ny runde med covid for å få fart på salgstallene igjen.
peak på noe over 100, nå er dere straks tilbake der den var før lufteturen kom.

Freddys · september 11, 2024, 5:15pm

Aker Carbon Capture, Arcticzymes Technologies, Cavendish Hydrogen, Rec Silicon og Ultimovacs blir ekskludert fra Hovedindeksen på Oslo Børs (OSEBX). De blir også tatt ut av fondsindeksen på Oslo Børs (OSEFX).

TekBot · september 16, 2024, 6:49am

ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation

Tromsø, Norway, September 16 2024 - ArcticZymes Technologies ASA (OSE:AZT), a
leading developer and manufacturer of high-quality enzymes for molecular
research, diagnostics, and therapeutics, is thrilled to announce the publication
…

Vis børsmeldingen

of a research paper in the prestigious international peer-reviewed journal
Nucleic Acid Research. The paper, entitled “Using nucleolytic toxins as
restriction enzymes enables new RNA applications,” showcases the unique features
and potential applications of a novel RNA restriction enzyme called ET-N1
(EcoToxN1).

Revolutionizing RNA Fragmentation: The patent-pending ET-N1 enzyme technology
represents a significant advancement in the field of RNA research, enabling
precise and controlled fragmentation of RNA molecules. This innovative tool
opens up new possibilities for analyzing and synthesizing RNA, paving the way
for the development of cutting-edge methodologies in the rapidly evolving field
of RNA research and therapeutics.

Unique Capabilities: What sets ET-N1 apart from other commercialized enzymes is
its ability to act as “molecular scissors,” offering functions that no other
enzyme can currently match. With the development of further variants,
ArcticZymes Technologies ASA is poised to revolutionize the landscape of RNA
modulation tools, empowering researchers and industry partners to push the
boundaries of scientific discovery and therapeutic innovation.

Collaborative Effort: The research paper, authored by Rothweiler et al., is the
result of a collaborative effort between ArcticZymes Technologies ASA and
esteemed academic and research institutions, including the University of Tromsø,
Norway, the Indian Institute of Science, Bangalore, India, and SINTEF Industry,
Trondheim, Norway. This collaborative endeavor was made possible through the
support of the Norwegian Research Council’s innovation grant “AdEPT - Advanced
Enzymes for Precision Therapeutics.”

Driving Progress and Innovation: Emphasizing ArcticZymes commitment to driving
progress and innovation in the field, CEO Michael Akoh comments: “Through
dissemination of our research findings in peer-reviewed journals, ArcticZymes
aims to elevate awareness of our cutting-edge products and stimulate the
emergence of disruptive technologies. We are committed to driving forward
progress in the field, providing enzymes that unlock new discoveries enabling
our partners’ development of tomorrows innovative technologies”.

Read the paper here: Using nucleolytic toxins as restriction enzymes enables new
RNA applications | Nucleic Acids Research | Oxford Academic
(oup.com) (https://academic.oup.com/nar/advance
-article/doi/10.1093/nar/gkae779/7756578?searchresult=1)

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who developing therapeutics,
in vitro diagnostics, and molecular research kit products. Our mission is to
make our customer’s lives easier by unlocking new solutions to enhance quality
of life and create a more sustainable, healthy world.

Kilde

TekBot · september 17, 2024, 6:32pm

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper published in Select Science on Advancing Viral Vector Manufacturing

September 17th, 2024, Tromsø, Norway - ArcticZymes Technologies (OSE: AZT) has
released a timely whitepaper in Select Science titled “Efficient Chromatin
Removal in Viral Vector Manufacturing Using Salt-Active Nucleases.” As global
…

Vis børsmeldingen

attention on salt-active nucleases increases, this whitepaper reinforces
ArcticZymes’ leadership by offering crucial insights that help viral vector
manufacturers optimize their downstream processing (DSP) and make informed
decisions.

The peer-reviewed studies cited in this paper will help leverage rising interest
about Salt Active Nucleases and guide the spotlight to ArcticZymes’ as the
pioneer. This will bring added awareness to products like M-SAN HQ which, these
studies show, demonstrate superior results for viral vector manufacturing,
particularly under physiological salt conditions.

The referenced studies demonstrate how M-SAN HQ efficiently fragments chromatin,
accelerating digestion times and leading to cleaner viral vector products with
fewer DSP steps. These advantages not only increase DSP efficiency and yield but
also significantly reduce costs-crucial benefits for today’s fast-growing
therapeutic virus manufacturing sector.

As the tide of interest in salt-active nucleases rises, ArcticZymes is well
-positioned to capitalize, with its cutting-edge enzyme solutions poised to
elevate the company’s influence in the evolving bioprocessing landscape.

Commenting on the release, Michael B. Akoh, CEO of ArcticZymes Technologies,
said: “The increasing focus on salt-active nucleases offers a significant
opportunity for ArcticZymes to showcase our leadership in the field. This
whitepaper underscores how our innovative solutions, such as M-SAN HQ, can
revolutionize viral vector manufacturing, helping our partners lower costs and
scale their operations more efficiently. At ArcticZymes, we understand that
bioprocessing is complex, and a ‘one size fits all’ approach doesn’t work.
That’s why we’ve created two specialized nucleases-M-SAN HQ for physiological
salt conditions and SAN HQ GMP for high salt environments. Together, these
enzymes deliver a complete solution for the entire viral vector production
process.”

To view the full white paper as published in Select Science click here:
https://cdn.prod.website
-files.com/64d5ee31f6ef966121388e81/66e9a2fcf995c33cd0554eb3_SAN%20Paper%20A4%202
024-09.pdf

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who developing therapeutics,
in vitro diagnostics, and molecular research kit products. Our mission is to
make our customer’s lives easier by unlocking new solutions to enhance quality
of life and create a more sustainable, healthy world.

Kilde

TekBot · september 19, 2024, 10:56am

ArcticZymes Technologies to present at the Pareto Securities 15th Healthcare Conference

tooeasy891 · oktober 17, 2024, 8:06am

Da har Chemometec oppjustert guidingen og Sartorius skriver i rapport i dag: Bioprocessing order intake +8.4%. Reiterated FY24 guide. “Most customers have largely completed the reduction of their inventories”. Aksjen +15% i dag.

Litt fra Oxford Biomedicas rapport for litt siden (troligvis den CDMOen som skal ta i bruk M-SAN for fremtidige lentiviral prosjekt):

“Successfully onboarded multiple new clients, including signing 7 early-stage AAV programmes in the US”

Client portfolio is maturing and now includes 37 clients and 48 programmes as of September 2024 (September 2023:24 clients and 41 programmes), representing a growth of 54% for clients and 17% for programmes year-on-year

The total potential revenue pipeline grew by 29% from $438 million to $565 million, since the start of the year (as of 13 September 2024)

We’ve experienced strong demand across our viral vector services, with particularly robust revenue growth in lentiviral vector manufacturing. https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1866803…

AZT ser kanskje ikke så dum ut om man tror på noe rundt konsensus 25/26e.

Staylong · oktober 17, 2024, 9:01am

Om det nå begynner å løsne litt, så er jo oppsiden ganske mye større enn nedsiden. Grunnmuren har jo blitt betydelig sterkere over de siste årene. Det som er tydelig er jo at de har vært høyt eksponert mot utviklingsprosjekter som er i tidlig fase. Det virker som om de i alle fall begynner å få en relativt stor kundemasse som kjøper mindre volum. En del av disse må jo øke volumene etter hvert som tiden går. Jeg hadde egentlig forventet at akkurat dette skulle gå litt raskere. Selv om vi ikke har inngående kjennskap til den nye strategien som de har omlagt til med ny CEO, så virker det fornuftig. Når de nå har disse fremragende produktene bør det jo være mulig å komme sterkere inn mot CDMO’ene . Spesielt når produktporteføljen øker med flere GMP-verifiserte produkter, samt nye og videreutviklede unike enzymer. Dokumentasjonen bygges opp sammen med eksterne parter, noe som bør gjøre salgsarbeidet enklere. Jeg kan ikke skjønne at ikke dette må begynne å slå ut i tallene snart. Vi har stått på stedet hvil hva gjelder inntekter noen år nå, så jeg håper at vi som er og har vært langsiktige får betalt snart. Eller er man bare blåøyde optimister?

tooeasy891 · oktober 17, 2024, 9:24am

Ja, det har vært noen tøffe år for alle i bransjen med lageroppbygging, høyere renter og mindre penger inn til smb / forskning.

Vi får håpe det ser bedre ut fremover, her er en graf fra en analytiker som følger Biotage hvor det kan se ut som at vi er forbi bunnen når det kommer til funding.

Blir spennende å se når azt kommer med som standardprodukt hos en CDMO og hva som kommer ut av OEM avtalene. Jeg tror hvertfall på en bedring i omsetning og resultat 2025 for azt.